The search for new adjuvants remains the critical task for the creation of hepatitis C vaccines due to the weak immunogenicity of biotechnological products. When immunizing mice with the recombinant proteins NS3 and NS5B of the hepatitis C virus (HCV), the adjuvant activity of three immunomodulators was compared. Phosprenyl® on the basis of polyprenyl phosphate (PPP), chemically synthesized analogue of the bacterial cell wall glucosaminyl muramyl dipeptide (GMDP), and IFN-α recombinant protein were tested. GMDP increased the activity of IgG1 antibodies 4–6 times but did not stimulate the production of IFN-γ; IFN-α has not shown any adjuvant properties. The introduction of recombinant HCV proteins together with PPP in low doses increased the...
The significant public health problem of Hepatitis C virus (HCV) has been partially addressed with t...
There are 3 to 4 million new hepatitis C virus (HCV) infections annually around the world, but no va...
A human cytomegalovirus (HCMV) glycoprotein B (gpUL55) DNA vaccine has been evaluated in BALB/c mice...
Although approximately 3% of the world's population is infected with Hepatitis C virus (HCV), there ...
Hepatitis C virus (HCV) is one of the main triggers of chronic liver disease. Despite tremendous pro...
Three decades after the discovery, hepatitis C virus (HCV) is still the leading cause of liver trans...
Three decades after the discovery, hepatitis C virus (HCV) is still the leading cause of liver trans...
Chronic hepatitis C virus (HCV) infection represents a major health threat to global population. In ...
Development of vaccination strategies against hepatitis C virus (HCV) is of paramount importance. Wi...
There are more than 350 million individuals with hepatitis C in the world. One of the important prob...
The development of an effective preventative hepatitis C virus (HCV) vaccine will reside, in part, i...
Chronic hepatitis C, which is caused by infection with the hepatitis C virus (HCV), is a global heal...
Although many studies provide strong evidence supporting the development of HCV virus-like particle ...
Neutralizing antibody responses elicited during infection generally confer protection from infection...
Neutralizing antibody responses elicited during infection generally confer protection from infection...
The significant public health problem of Hepatitis C virus (HCV) has been partially addressed with t...
There are 3 to 4 million new hepatitis C virus (HCV) infections annually around the world, but no va...
A human cytomegalovirus (HCMV) glycoprotein B (gpUL55) DNA vaccine has been evaluated in BALB/c mice...
Although approximately 3% of the world's population is infected with Hepatitis C virus (HCV), there ...
Hepatitis C virus (HCV) is one of the main triggers of chronic liver disease. Despite tremendous pro...
Three decades after the discovery, hepatitis C virus (HCV) is still the leading cause of liver trans...
Three decades after the discovery, hepatitis C virus (HCV) is still the leading cause of liver trans...
Chronic hepatitis C virus (HCV) infection represents a major health threat to global population. In ...
Development of vaccination strategies against hepatitis C virus (HCV) is of paramount importance. Wi...
There are more than 350 million individuals with hepatitis C in the world. One of the important prob...
The development of an effective preventative hepatitis C virus (HCV) vaccine will reside, in part, i...
Chronic hepatitis C, which is caused by infection with the hepatitis C virus (HCV), is a global heal...
Although many studies provide strong evidence supporting the development of HCV virus-like particle ...
Neutralizing antibody responses elicited during infection generally confer protection from infection...
Neutralizing antibody responses elicited during infection generally confer protection from infection...
The significant public health problem of Hepatitis C virus (HCV) has been partially addressed with t...
There are 3 to 4 million new hepatitis C virus (HCV) infections annually around the world, but no va...
A human cytomegalovirus (HCMV) glycoprotein B (gpUL55) DNA vaccine has been evaluated in BALB/c mice...